Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AKU CVE:LXG NASDAQ:ONC CVE:SQD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkuminC$0.00C$0.16▼C$1.90C$37.20M0.157,202 shs12,903 shsLXGLexaGeneC$0.11-19.2%C$0.11C$0.07▼C$0.31C$14.77M2.26170,061 shs2.14 million shsONCBeOne Medicines$310.25+0.2%$300.77$235.35▼$385.22$34.04B0.5230,234 shs190,918 shsSQDSQI DiagnosticsC$0.02C$0.02C$0.01▼C$0.18C$6.11M-0.21172,133 shs65,000 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%LXGLexaGene0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines0.00%+5.79%+3.48%-14.33%+31.19%SQDSQI Diagnostics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkuminC$0.00C$0.16▼C$1.90C$37.20M0.157,202 shs12,903 shsLXGLexaGeneC$0.11-19.2%C$0.11C$0.07▼C$0.31C$14.77M2.26170,061 shs2.14 million shsONCBeOne Medicines$310.25+0.2%$300.77$235.35▼$385.22$34.04B0.5230,234 shs190,918 shsSQDSQI DiagnosticsC$0.02C$0.02C$0.01▼C$0.18C$6.11M-0.21172,133 shs65,000 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%LXGLexaGene0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines0.00%+5.79%+3.48%-14.33%+31.19%SQDSQI Diagnostics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/ALXGLexaGene 0.00N/AN/AN/AONCBeOne Medicines 2.80Moderate Buy$389.1525.43% UpsideSQDSQI Diagnostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKU, ONC, YGEN, LXG, and SQD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ONCBeOne Medicines Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$364.00 ➝ $367.005/7/2026ONCBeOne Medicines Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$395.005/7/2026ONCBeOne Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$410.00 ➝ $420.005/7/2026ONCBeOne Medicines BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $409.005/7/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$423.00 ➝ $425.005/7/2026ONCBeOne Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$411.00 ➝ $413.005/4/2026ONCBeOne Medicines Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$400.005/4/2026ONCBeOne Medicines Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026ONCBeOne Medicines Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ONCBeOne Medicines Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$340.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkuminC$737.69M0.00N/A1.96C($2.86) per share0.00LXGLexaGeneC$110.93K133.13C$0.00 per share21.25C$0.01 per share10.50ONCBeOne Medicines$5.34B6.37$3.91 per share79.38$43.39 per share7.15SQDSQI DiagnosticsC$3.04M2.01C$0.00 per share8.50C($0.04) per share-0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-C$255.80M-C$3.80N/AN/AN/A-34.67%-483.86%0.47%N/ALXGLexaGene-C$8.54M-C$0.08N/AN/AN/AN/A-339.54%-120.21%N/AONCBeOne Medicines$286.93M$4.4769.4129.92N/A8.94%12.06%6.69%N/ASQDSQI Diagnostics-C$19.14M-C$0.05N/AN/AN/AN/AN/A-74.70%N/ALatest AKU, ONC, YGEN, LXG, and SQD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billion2/26/2026Q4 2025ONCBeOne Medicines$1.60$0.58-$1.02$0.58$1.45 billion$1.50 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ALXGLexaGeneN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ASQDSQI DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin266,886.350.121.03LXGLexaGene138.011.391.13ONCBeOne Medicines0.203.643.27SQDSQI Diagnostics464.330.120.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin30.27%LXGLexaGene0.09%ONCBeOne Medicines48.55%SQDSQI Diagnostics25.15%Insider OwnershipCompanyInsider OwnershipAKUAkumin32.95%LXGLexaGene17.85%ONCBeOne Medicines6.19%SQDSQI Diagnostics50.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin1,52770.18 millionN/ANot OptionableLXGLexaGene41140.64 millionN/ANot OptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ASQDSQI Diagnostics147,000407.17 millionN/ANot OptionableAKU, ONC, YGEN, LXG, and SQD HeadlinesRecent News About These CompaniesArchival Footage of D-DayNovember 1, 2024 | smithsonianmag.comSHow bioinformatics is revolutionizing genetic diagnostics?August 3, 2024 | dqindia.comDBVAXF BioVaxys Technology Corp.March 28, 2024 | seekingalpha.comSQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy FilingJune 16, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - SQDJune 6, 2023 | finance.yahoo.comThis SQI Diagnostics Insider Increased Their Holding In The Last YearMay 18, 2023 | finance.yahoo.comClosing Bell: Sqi Diagnostics Inc flat on Friday (SQD)May 17, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc up on Friday (SQD)April 29, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc up on Wednesday (SQD)April 26, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc down on Monday (SQD)April 25, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc down on Thursday (SQD)April 21, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc down on Friday (SQD)April 15, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc flat on Wednesday (SQD)April 12, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc flat on Tuesday (SQD)April 11, 2023 | theglobeandmail.comSQI DIAGNOSTICS ANNOUNCES ISSUANCE OF PREVIOUSLY ANNOUNCED BONUS WARRANTSMarch 20, 2023 | finance.yahoo.comSQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND DEFERRAL OF CERTAIN INTEREST PAYMENTSFebruary 6, 2023 | ca.finance.yahoo.comThe Independent Director of SQI Diagnostics Inc. (CVE:SQD), Gerald Connor, Just Bought 5.8% More SharesDecember 9, 2022 | finance.yahoo.comSQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND ANNOUNCES DEFERRAL OF CERTAIN INTEREST PAYMENTSOctober 19, 2022 | finance.yahoo.comSQI Diagnostics: Top 10 Undervalued Medical Diagnostics & Research Industry Sector Stocks on TSX Venture Exchange (SQD)September 18, 2022 | theglobeandmail.comSQI Diagnostics reports Q3 resultsAugust 30, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBerkshire Hathaway’s Record Cash Hoard: Why and What's Next?By Chris Markoch | May 5, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 2026Spotify’s Ad Slump Raises a Bigger Question Than You ThinkBy Chris Markoch | April 29, 20263 Emerging Markets ETFs to Maximize Exposure to High-Potential CountriesBy Nathan Reiff | May 4, 2026Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30%By Leo Miller | May 6, 2026AKU, ONC, YGEN, LXG, and SQD Company DescriptionsAkumin TSE:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida. On October 22, 2023, Akumin Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.LexaGene CVE:LXGC$0.10 -0.03 (-19.23%) As of 02/21/2023LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.BeOne Medicines NASDAQ:ONC$310.25 +0.63 (+0.20%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$305.65 -4.60 (-1.48%) As of 05/22/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.SQI Diagnostics CVE:SQDC$0.02 0.00 (0.00%) As of 06/14/2023SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
